LOS ANGELES and CAMBRIDGE, Mass., Aug. 13, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that Abbie Celniker, Ph.D. has joined the company as a Director and Chair of the Board.
"In ImaginAb's search for Board leadership, we set out to attract an industry visionary with perspective from big biopharma as well as entrepreneurial experience and we have found all of these qualities in Dr. Celniker." said Christian Behrenbruch, Ph.D., Chief Executive Officer of ImaginAb. "We are delighted to welcome Dr. Celniker to our team and look forward to her contributions as we develop our groundbreaking in vivo molecular imaging agents."
"Companion diagnostic strategies are increasingly critical to new therapeutic management strategies in the oncology and immunology space," commented Dr. Celniker. "ImaginAb's platform for re-engineering therapeutic antibody drugs into imaging agents is unique in the industry and bears great potential. ImaginAb is beginning to realize the promise of this technology by advancing its internal clinical pipeline in cancer and autoimmune diseases, as well as multiple collaborations with biopharma."
Abbie Celniker, Ph.D., is currently President and CEO of Eleven Biotherapeutics (Cambridge, MA) and brings more than 20 years of proven expertise in building protein discovery and development programs and biologics-focused businesses. Prior to Eleven Biotherapeutics, she led Taligen, which was acquired by Alexion Pharmaceuticals in 2011. Dr. Celniker was formerly the global head of biologics at Novartis, where she forged strategic alliances and led internal discovery and development to build the pipeline. Earlier in her career, Dr. Celniker spent more than six years at Millennium Pharmaceuticals as senior vice president, R&D strategy and operations and head of biotherapeutics and pharmaceutical sciences. She also held development roles with Wyeth BioPharma (Genetics Institute) and Genentech.
ImaginAb is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of personalized medicine by improving patient outcomes and reducing the cost of healthcare.
For more information, visit www.imaginab.com.
SOURCE ImaginAb, Inc.